1. Cannabinoid CB1 receptor antagonists in therapeutic and structural perspectives;JHM Lange;Chem Rec,2008
2. EMEA. EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) ACOMPLIA EPAR summary for the public. 2009; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Summary_for_the_public/human/000666/WC500021282.pdf.
3. EMEA. PUBLIC STATEMENT ON Acomplia (rimonabant) WITHDRAWAL OF THE MARKETING AUTHORISATION IN THE EUROPEAN UNION. 2009; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2009/11/WC500012189.pdf.
4. The future of endocannabinoid-oriented clinical research after CB(1) antagonists;B Le Foll;Psychopharmacology,2009
5. FDA. FDA Briefing Document NDA 21–888—Zimulti (rimonabant). 2007; Available from: http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4306b1-fda-backgrounder.pdf.